Navigation Links
Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO

BERKELEY HEIGHTS, N.J., June 04, 2007 /PRNewswire-FirstCall/ -- Genta Incorporated announced the presentation of results from a Phase 2 clinical trial of its marketed product, Ganite(R) (gallium nitrate injection), plus rituximab (Rituxan(R); Genentech/IDEC) and dexamethasone in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). The data were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

Previously published studies have indicated that high doses of gallium nitrate used alone or in combination with chemotherapy showed preliminary evidence of clinical activity in patients with Hodgkin's disease and non- Hodgkin's lymphoma. Based on these data, investigators at Loyola University Medical Center sought to incorporate gallium nitrate into a minimally myelosuppressive "salvage" regimen (called "GaRD") that was designed to treat patients who had failed multiple types of standard therapy.

In the GaRD trial, gallium nitrate was administered in combination with rituximab and dexamethasone. Twenty-two patients with NHL were entered into this study, most of whom had been refractory to multiple salvage therapies. All patients had failed prior treatment with rituximab, including 18 of 22 who received rituximab in their last regimen. Overall, 41% of patients achieved a major objective response, including 8 (36%) with complete or unconfirmed complete responses and 1 (5%) with a partial response. Two of the major responders had previously failed a stem cell transplant; both patients remain in sustained remission 14+ and 18+ months after their last relapse. Six other patients achieved stable disease. Five patients subsequently underwent a stem cell transplant. Of all 22 patients treated with the GaRD regimen, 46% are alive at a median followup of 17+ months, and 7 are currently without evidence of disease.

No non-hematologic Grade 4 advers
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/5/2008)... 5 /PRNewswire-USNewswire/ -- Cancer patients,have...s chemobrain. Now in,animal studies at West Virgin...jections of N-acetyl cysteine (NAC), an antioxidan...chemotherapy drugs sometimes induce., In the WVU ...ue of the,journal Metabolic Brain Disease, rats we...
(Date:9/4/2008)...pt. 4 /- Cytopia Limited (ASX:,CYT) t... its Phase Ib/II,study of CYT997, the company,s no...nts with an aggressive form of brain cancer known ...al trial is the first Phase II efficacy study in h...mpany and the second in its,suite of Phase II stud...
(Date:9/4/2008)...stetrician-Gynecologists States UFE Meets Level,A ...vasive Interventional,Radiology Treatment Is Safe,... FAIRFAX, Va., Sept. 4 /PRNewswire-USNewswire/ --...al organization of nearly 4,500 doctors,scientist...roving health,care through minimally invasive trea...
(Date:9/4/2008)... potent antiviral activity and favorable safety ... Mass., Sept. 4 /- Idenix,P...ceutical company engaged,in the discovery and deve...and other infectious diseases, today announced tha...uating IDX899, a non-nucleoside reverse,transcript...
Breaking Medicine Technology:Study Suggests a Possible Way to Offset Chemobrain Memory Loss 2Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 2Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Laureate Announces Manufacturing Agreement with ARIUS for Trop 2 Targeting Antibody 2883 1Laureate Announces Manufacturing Agreement with ARIUS for Trop 2 Targeting Antibody 2883 2Laureate Announces Manufacturing Agreement with ARIUS for Trop 2 Targeting Antibody 2883 3Koronis Pharmaceuticals Announces Appointment of Daniel H Petree and George R Painter Ph D to Board of Directors 2880 1Koronis Pharmaceuticals Announces Appointment of Daniel H Petree and George R Painter Ph D to Board of Directors 2880 2Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology 2877 1Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology 2877 2Amsterdam Molecular Therapeutics to Appoint Philippe van Holle 28Celgene 29 to Supervisory Board 2874 1Amsterdam Molecular Therapeutics to Appoint Philippe van Holle 28Celgene 29 to Supervisory Board 2874 2Amsterdam Molecular Therapeutics to Appoint Philippe van Holle 28Celgene 29 to Supervisory Board 2874 3
...April 16, 2007 /PRNewswire-FirstCall/ --,Threshold...presentations regarding its oncology pipeline, whi...ypoxically Activated Prodrug,TH-302, and two rese...tor program. The presentations will take place at ...(AACR) annual meeting,being held April 14 - 18, 20...
...WIRE)--Apr 16, 2007 - ZIOPHARM Oncology,Inc. (NAS...clinical,data for an orally active form of ZIO-201...Association of Cancer Research meeting being,held ...vailability,of ZIO-201 and activity in a variety o...IFOS) and cyclophosphamide resistant tumors.,An or...
Other Medicine Technology:Threshold Pharmaceuticals Announces Multiple Presentations on,Oncology Pipeline at the 2007 American Association for Cancer,Research (AACR) Annual Meeting 2Threshold Pharmaceuticals Announces Multiple Presentations on,Oncology Pipeline at the 2007 American Association for Cancer,Research (AACR) Annual Meeting 3ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR 2ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR 3
(Date:9/5/2008)..., could bring objects out of hiding , , ...omeone develops a cloak of invisibility, a team of...he objects it hides. , According to a paper pub...rneath an invisibility cloak would allow invisible...nghai Jiao Tong University in China said their the...
(Date:9/5/2008)...develop a National AIDS,Strategy for the U.S., MI...USNewswire/ -- The,Republican National Convention ...ic AIDS epidemic in the United States and only pas...residential nominee Sen. John McCain nor,Vice Pres...n their remarks,to Convention delegates., The Rep...
(Date:9/5/2008)... -- Speaker Nancy Pelosi,issued the following stat...p to Cancer" telethon, to be aired on all networks...who has not seen a loved one,suffer because of can...each,year there are more than 1.4 million new case...ating the scourge of cancer a national priority of...
(Date:9/5/2008)... Tonight is a momentous,occasion as the three majo...utives, celebrities and prominent leaders in cance...nd Up to Cancer. This collaboration,featuring a o...n the three,networks -- ABC, CBS and NBC -- offers...on about cancer and the need to take action., For...
Breaking Medicine News(10 mins):Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3Health News:The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years 2
...rder in human faculties" increases dependence on o...esident A.P.J. Abdul Kalam Wednesday urged researc...sense of equality among children affected by autis...evention, early detection, appropriate training to...
...gram developed by researchers now at the Universit...e used to study how individuals with sickle cell d...erited blood disorder.// The $2.9 million four-y...t the University of Illinois Medical Center at Chi...
... has said that it will undertake the subjects of b...uence all the genetic changes that lead to cancer....nome Atlas project will pinpoint hundreds or thous... that it can be used to develop better drugs to tr...
...ssociation (IHCA) has said the hearings by the Med...inuation of the present practice//, which is again...hearing in specific circumstances. The new recomme...itional charge over appointments and control of th...
Other Medicine News:Health News:Autistic Children Need Sense of Equality: A.P.J. Abdul Kalam 2Health News:Computer May Improve Pain Relief for Sickle Cell Patients 2
Hemispheric Sound Technology, multi-frequency, linear micro-surgery transducer. This unique tiny transducer is very helpful in tight situations. It has proven to be a choice transducer for pediatric
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer.
Super High Density, multi frequency Side Fire "T intraoperative transducer. A narrower field of view is this transducers benefit for when scanning in smaller abdomens or in tighter spaces.
Super High Density, 120 field of view, angled handle, multi-frequency, convex endovaginal transducer.
Medicine Products: